GLP-1 TV
Oral GLP-1 Pill Orforglipron from Eli Lilly | Here’s What You Need to Know
Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
According to the video, Eli Lilly's oral GLP-1 medication orforglipron is in phase three clinical trials for type 2 diabetes, for weight management in adults with obesity or overweight and at least one weight related health condition, and for obstructive sleep apnea in people with obesity. The creator says, citing Eli Lilly's investor reports, that the trials have shown statistically significant results and a safety profile very similar to injectable GLP-1 medications.
Published by Beyond the Scale: My GLP-1 Journey on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
The creator reports that orforglipron lowered A1C by an average of 1.3 to 1.6, with larger reductions at higher doses. In a 40 week trial of people averaging about 198.9 pounds, she says participants lost 9.3 pounds at 3 mg, 11.5 pounds at 12 mg and 15.8 pounds at 36 mg, compared with about 3.4 pounds on placebo. Side effects are described as similar to the injectables, such as nausea or diarrhea.
For comparison, the video cites a 72 week Zepbound study with average losses of 34 pounds at 5 mg, 44 pounds at 10 mg and about 48 pounds at 15 mg, versus about 7 pounds on placebo. The creator says Zepbound currently delivers more weight loss, but that the pill could suit people who prefer not to inject. On cost, she says there is no official price, that launch is probably late 2025 or early 2026, and that reports suggest $500 to $1,000 a month. She adds that it is unlikely to be significantly cheaper than the oral semaglutide product Rybelsus.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:37 The creator outlines what the video covers: trial results, comparison with injectables like Zepbound, possible pricing and what it could mean for care.
- 1:08 She says orforglipron is in phase three trials for type 2 diabetes, weight management and obstructive sleep apnea in people with obesity.
- 1:38 She reports A1C reductions averaging 1.3 to 1.6, depending on dose.
- 1:51 In a 40 week trial, she says average loss was 9.3 pounds at 3 mg, 11.5 pounds at 12 mg and 15.8 pounds at 36 mg, versus about 3.4 pounds on placebo.
- 2:41 She cites a 72 week Zepbound study with average losses of 34, 44 and about 48 pounds at 5 mg, 10 mg and 15 mg doses.
- 3:42 She says there is no official price, launch is probably late 2025 or early 2026, and reports suggest $500 to $1,000 a month.
Key moments
Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Zepbound and Foundayo
Questions this video answers
How much weight did people lose on orforglipron in trials?
According to the video, in a 40 week trial of people averaging about 198.9 pounds, the average loss was 9.3 pounds at 3 mg, 11.5 pounds at 12 mg and 15.8 pounds at 36 mg. The placebo group lost about 3.4 pounds.
How does orforglipron compare to Zepbound for weight loss?
The creator says Zepbound currently delivers more dramatic weight loss, citing a 72 week study with average losses of 34 to about 48 pounds depending on dose. She suggests orforglipron could be an alternative for people who prefer pills over injections.
How much will orforglipron cost and when will it be available?
The creator says there is no official price yet and that it probably will not reach the market until late 2025 or early 2026. She says reports suggest $500 to $1,000 a month.
What are the side effects of orforglipron?
According to the video, side effects are similar to injectable GLP-1 medications, with gastrointestinal issues such as nausea or diarrhea. The creator says nothing is too surprising for those familiar with how GLP-1s work.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Orforglipron: Newest Weight Loss Drug | Game Changer Or Looming Risk? | India TodayAccording to the video, the channel presenter walks through Eli Lilly's experimental daily weight loss pill, orforglipron.- What a GLP-1 costs at every program we trackToday’s lowest is $39/mo. Every program ranked by price alone. Compounded drugs are not FDA-approved.
Shaquielle O'Neal Just Confirmed He's on Zepbound!This weekly news episode from the hosts of the channel covers eight GLP-1 stories.
Orforglipron for Obesity Treatment (ATTAIN-1) | NEJM | Med Journal ClubAccording to the video, the ATTAIN-1 trial tested once-daily orforglipron, an oral small-molecule GLP-1 agonist, in adults with obesity who do not have diabetes.
Foundayo Explained: The New Oral GLP-1 Weight Loss Pill FDA Just Approved 💊According to the video, the FDA has approved Foundeo, the brand name for orforglipron from Eli Lilly.
FDA approves weight loss drug Zepbound to treat sleep apneaIn this segment, medical correspondent the speaker explains that the FDA has approved Zepbound for obstructive sleep apnea.
BREAKING NEWS: Orforglipron Maintains Weight After GLP-1 InjectionsThe speaker of another speaker says Eli Lilly made two linked announcements about orforglipron, its once daily oral GLP-1 drug.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Foundayo: the GLP-1 pill where buying direct is the cheap route
Lilly's oral GLP-1 was approved on 1 April 2026, and it does something no other weight-loss pill does: you take it any time of day, with or without food. The pricing is the surprising part. Lilly self-pay starts at $149 a month, and the one telehealth program on our board selling it, Sesame Care, charges $208 once its membership fee is counted. That reverses the usual arithmetic in this market, and the reason is simple: orforglipron is a new small molecule under patent, so there is no compounded version to undercut it.
- Zepbound for sleep apnea: what the label approves, what SURMOUNT-OSA found, and who pays for it
Zepbound is the only GLP-1 approved to treat moderate to severe obstructive sleep apnea, in adults with obesity, alongside diet and exercise. In the two 52-week SURMOUNT-OSA trials, breathing interruptions fell by about 25 to 29 events an hour on Zepbound against about 5 on placebo. The label's OSA maintenance dose is 10 mg or 15 mg a week. Because sleep apnea is a medical indication, Medicare's GLP-1 Bridge excludes it and points people to their Part D plan, which may cover it.
- What is Zepbound? Tirzepatide explained: what it treats, how it works, and what it costs
Zepbound is Eli Lilly's brand of tirzepatide, a once-weekly injection that acts on two hormone receptors, GIP and GLP-1. The FDA label approves it, with diet and exercise, for weight reduction in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-5 trial it produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. Lilly sells it self-pay from $299 a month.
Next steps
Foundayo prices
Find more like it
Side effectsDose changeWeigh-in and resultsInjection techniqueCost and insuranceThe trials
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















